ArticleChemistry & biodiversity2026
Antimicrobial Activity of Cinnamomum cassia Essential Oil: Phytochemical Profiling, In Vitro Evaluation, and Molecular Docking.
Article in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, Cinnamomum cassia bark essential oil (CEO) was extracted with a yield of 2.51% and characterised by its organoleptic properties, physicochemical characteristics, and gas chromatography-mass spectrometry (GC-MS) profiling. Seven phytoconstituents were identified, with (E)-cinnamaldehyde predominating (87.14%). CEO inhibited Staphylococcus aureus ATCC 25923, Bacillus subtilis ATCC 6633, Escherichia coli ATCC 25922, and Pseudomonas aeruginosa ATCC 27853, with inhibition zones of 16.0 ± 1.0-47.0 ± 1.0 mm. Minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) values ranged from 0.52-1.04 and 0.52-2.08 mg/mL, respectively, with greater susceptibility observed among the gram-positive strains. Antifungal evaluation revealed potent activity against Alternaria alternata and moderate activity against Aspergillus niger, with direct-contact exposure showing greater inhibition of As. niger than vapour-phase treatment. Molecular docking identified coumarin, a minor constituent, as exhibiting the strongest predicted binding, with binding energies of -7.7 kcal/mol against the bacterial targets TEM-1 β-lactamase and D-alanine:D-alanine ligase, and -7.0 kcal/mol against tyrosyl-tRNA synthetase. Coumarin also showed favorable predicted binding to the fungal targets cytochrome P450 51B (CYP51B) and epoxide hydrolase. These findings support the potential of CEO as a natural antimicrobial preservative, although further validation in real food systems is required.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.